October 30, 2018 08:02 AM EDTUpdated 08:17 AM

Terns scores $80M in Series B financing led by Vivo, OrbiMed

ENDPOINTS

Transpacific biotech upstart Terns Pharmaceuticals, which is focused on developing treatments for NASH and cancer, has closed $80 million in Series B financing as it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Terns scores $80M in Series B financing led by Vivo, OrbiMed

ENDPOINTS

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Terns scores $80M in Se­ries B fi­nanc­ing led by Vi­vo, Or­biMed

ENDPOINTS

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

Terns scores $80M in Series B financing led by Vivo, OrbiMed

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases